Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
EIF5A2 (eukaryotic translation initiation factor 5A2) is a conserved acidic protein with a relatively small molecular mass (1.7×104) in the EIF family. The two subtypes of EIF5A in human EIF5A1 have 84% amino acid sequence homology and 94% similarity to EIF5A2, which are encoded by translation initiation factor 51A (TIF 51A) and TIF 51B genes, respectively. However, the biological functions of these two subtypes may vary significantly. EIF5A1 is present in almost all tissues and cells and plays an important role in RNA metabolism and translation elongation. While EIF5A2 is tissue and cell-specific, its mRNA is expressed only in specific tissues (eg, testicular tissue, brain tissue, or part of malignant tumor tissue) and cells.
Characteristic Structure and Biological Function of EIF5A2 Gene
Unlike members of other EIF families, the primary structure of EIF5A2 and EIF5A1 has a polyamine-derived amino acid 8-hydroxy 2,7,10-triaminodecanoic acid. Deoxyhypusine synthase (DHS) and deoxyhypusine hydroxylase (DOHH) mediated 8-hydroxy 2,7,10-triaminodecanoic acid modification on lysine 50 residues. This modification plays a crucial role in catalyzing the post-translational modification and activation of EIF5A2. The 8-hydroxy 2,7,10-triaminodecanoic acid modification is a post-translational modification process unique to the EIF5A protein.
Figure 1. Modification and subcellular location of EIF5A2. (Wang, et al. 2015)
After modification with DHS and DOHH, the EIF5A2 protein is converted to a mature active form. Nuclear EIF5A2 complexed with RanGTP and XPO4 mediates the export of mature EIF5A2. However, if acetylation of lysine-47 occurs, EIF5A2 may also accumulate at the nucleus. Li et al. found that EIF5A2 is involved in mRNA-related transcription, translation, and nuclear transport functions, especially in the translation process. EIF5A2 is an upstream regulator of cellular protein synthesis. Any subtle changes in translation initiation factors can lead to large changes in downstream target genes and pathways, resulting in certain biological behavioral changes.
Expression of EIF5A2 in Malignant Tumors
The study found that EIF5A2 is overexpressed in a variety of malignancies(eg nasopharyngeal carcinoma, non-small cell lung cancer, breast cancer, gastric cancer, esophageal squamous cell carcinoma, liver cancer, colorectal cancer, bladder cancer, prostate cancer, cervical cancer, ovarian cancer, malignant melanoma, leukemia, etc.), suggesting that EIF5A2 acts as an oncogene in tumor progression.
The expression of EIF5A2 is closely related to the clinical stage and grade of multiple malignancies. At the same time, EIF5A2 overexpression is closely related to the survival rate of patients with malignant tumors. The 5-year survival rate and disease-free survival rate of EFI5A2 overexpressing patients are low. The expression of EIF5A2 can be used as an independent predictor of poor prognosis in these cancer patients. Moreover, EIF5A2 overexpression is closely related to lymph node metastasis, distant metastasis and vascular metastasis in tumor patients such as esophageal squamous cell carcinoma, liver cancer, colorectal cancer, cervical cancer and malignant melanoma. These findings suggest that EIF5A2 can be used as a prognostic marker for a variety of human tumors.
Huang et al. found that EIF5A2 expression was not significantly associated with age, gender, and clinical stage in patients with nasopharyngeal carcinoma. Yang et al. showed that there was no significant correlation between EIF5A2 expression and gender, age and tumor differentiation in patients with esophageal squamous cell carcinoma, but it was positively correlated with tumor invasion depth. EIF5A2 is an oncogene that undergoes gene amplification in a variety of malignancies. Overexpression of EIF5A2 is closely related to the progression, invasion and postoperative recurrence of malignant tumors. Inhibition of EIF5A2 expression inhibits proliferation of a variety of tumor cells.
Molecular Mechanism of EIF5A2 in Related Tumors
Li et al. found that EIF5A2 is an upstream regulator of the hypoxia-inducible factor-1α (HIF-1α) promoter. EIF5A2 may increase the transcriptional activity of HIF-1α by binding to the HIF-1α promoter region-2000 bp to~1500 bp fragment. EIF5A2 promotes EMT and is positively correlated with the expression of vascular endothelial growth factor (VEGF). In esophageal squamous cell carcinoma, tissue hypoxia leads to the interaction of EIF5A2 with HIF-1α, which in turn leads to up-regulation of EIF5A2 expression and plays an important role in tumor invasion, metastasis and angiogenesis. Tian et al. found that the expression of microRNA (miR)-30b is down-regulated in gastric cancer, and it acts as an inhibitor in tumor cells. miR-30b is located in the 3'-untranslated region (3'-UTR) of EIF5A2 mRNA, suggesting that EIF 5A 2 may be a target gene of miR-30b. And it plays a role in EMT. miR-30b may inhibit the transfer of tumor cells by down-regulating the expression of EIF5A2 and inhibiting EMT.
In liver cancer, EIF5A2 leads to cytoskeletal remodeling by activating Ras homologous oncogenes(Rho) and Ras-associated C3 botulinum toxin substrate 1, Rac1, the Rho/Rac1 pathway and EMT. This plays an important role in the invasion and progression of liver cancer. Fujimura et al. found that EIF5A2 overexpressing pancreatic cancer promotes pancreatic cancer cell proliferation by up-regulating the level of pseudopodium enriched atypical kinase 1 (PEAK1) and the activity of Src family kinase (SFK). The K-Ras/EIF5A2/PEAK1 signaling pathway is critical in the development of pancreatic ductal adenocarcinoma. Deng et al. found that the expression of EIF5A2 was negatively correlated with the expression of miR-203 in colon cancer tissues. EIF5A 2 is a downstream target gene for the direct action of miR-203. miR-203 inhibits proliferation, invasion, and metastasis of colon cancer cells by inhibiting EIF5A2 expression.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.